港股異動 | 持續獲回購 四環醫藥(0460.HK)盤中漲近8%
格隆匯10月20日丨此前大跌的四環醫藥(0460.HK)近日累計反彈20%。今日盤中一度漲近8%,報1.77港元,目前漲幅收窄至4.12%,成交額放大至1.19億港元,總市值167.3億港元。15日公司以每股1.63-1.56港元回購了1437.1萬股,耗資2311.14萬港元;8日亦回購600萬股,涉資942.12萬港元。有分析人士指出,公司成功向醫美及高質量醫藥轉型,表現令人鼓舞。另外,集團在上半年已簽訂協議獨家代理引進韓國東方醫療株式會社旗下的可吸收縫線和無張力尿道懸吊帶兩類產品,可快速上市銷售。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.